Company’s revenue from operations in the quarter grew 15% to Rs 5,842 crore versus Rs 5,086 crore in Q1FY25.
The PAT was 11% higher on a sequential basis versus Rs 390 crore in Q4FY25 while the topline increased 4.5% over Rs 5,592 reported by the company in Q4FY25.
The earnings were announced after market hours and Apollo Hospitals shares ended with minor downtick at Rs 7,253 on the NSE.
Segment revenue
The company earned its revenues from healthcare services, Retail health & diagnostics, Digital health & pharmacy distribution and also as other income.
— Healthcare services revenue stood at Rs 2,974 crore in Q1FY26 versus Rs 2,843 crore in Q4FY25 and Rs 2,654 crore in Q1FY25.
— Retail health & diagnostics revenue stood at Rs 435 crore in Q1FY26 versus Rs 394 crore in Q4FY25 and Rs 366 crore in Q1FY25.
— Digital health & pharmacy distribution revenue stood at Rs 2,472 crore in Q1FY26 versus Rs 2,376 crore in Q4FY25 and Rs 2,082 crore in Q1FY25.
Also Read: Nykaa Q1 Results: Cons PAT soars 79% YoY to Rs 24 crore, revenue jumps 23%
Q1 Expenses
The company’s expenses were reported at Rs 5,313 crore, up on a YoY and QoQ basis. In the previous quarter, Apollo Hospitals had reported expenses of Rs 5,148 crore while Rs 4,704 crore in the year ago period. The expenses were made on material used by the hospital, purchases of stock-in-trade, employee benefits and as finance cost.
Acquisition
The company’s Board of Directors today approved an investment of Rs 8.5 crore for acquiring 85 lakh equity shares of Apollo Gleneagles PET-CT Private Limited (AGPCL) from its existing shareholder, Parkway Healthcare (Mauritius) PTE Limited, representing capital of AGPCL.
Also Read: NSDL Q1 Results: Cons PAT jumps 15% YoY to Rs 90 crore despite 7% drop in revenue
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
